Navigation Links
Moffitt researchers develop process to help personalize treatment for lung cancer patients
Date:6/3/2014

TAMPA, Fla. (June 3, 2014) Moffitt Cancer Center researchers, in collaboration with the Lung Cancer Mutation Consortium, have developed a process to analyze mutated genes in lung adenocarcinoma to help better select personalized treatment options for patients. Adenocarcinoma is the most common type of lung cancer in the United States with approximately 130,000 people diagnosed each year.

The study, published in the May 21 issue of The Journal of the American Medical Association, investigated 10 highly mutated and altered genes that contribute to cancer progression, termed oncogenic driver genes, in more than 1,000 lung cancer patients. Patients with adenocarcinoma have a high probability of having mutated oncogenic driver genes in their tumors.

As new oncogenic driver genes are identified, the testing process becomes less efficient because more genes need to be analyzed in limited amounts of tumor tissue. The researchers developed a process to analyze multiple genes at one time with small amounts of patient tissue. They found that 64 percent of lung adenocarcinoma patients had at least one oncogenic driver gene.

Patients who had mutations were offered therapies targeted to their specific mutation. The researchers found that those patients who had targeted treatment against an oncogenic driver gene survived longer than those patients who did not.

"Precision medicine is the future of cancer care. We are continuing this study by attempting to profile all advanced lung adenocarcinoma patients for driver genes to match them with appropriate therapies," explained Eric B. Haura, M.D., director of Moffitt's Lung Cancer Center of Excellence. "We'd like to extend this further to examine for driver genes in other types of lung cancer, such as squamous cell lung cancer."

The researchers also plan to use this technology to study drug resistance and are developing additional platforms to guide decision making in the clinic.

Since the Lung Cancer Mutation Consortium trial began in 2009, many patients are now tested for mutated or altered genes before treatment. This study is the first of its kind that supports the concept that the simultaneous analysis of genetic mutations is possible with the goal of delivering more personalized medicine.


'/>"/>

Contact: Kim Polacek
Kim.Polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt researchers find cancer therapies affect cognitive functioning among breast cancer survivors
2. Moffitt Cancer Center researchers: Quality of life as important as quantity of life
3. Moffitt Cancer Center researchers working at frontiers of melanoma research
4. Moffitt researchers find adolescents with cancer concerned about their future reproductive health
5. Moffitt researcher publishes book on nutritional management of cancer treatment effects
6. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
7. Researchers creating designer lymph nodes based on Moffitts Total Cancer Care initiative
8. Moffitt Cancer Center researchers identify drivers of sarcoma growth and survival
9. Moffitt Cancer Center researchers develop and test new anti-cancer vaccine
10. Moffitt researcher, colleagues find success with new immune approach to fighting some cancers
11. Moffitt researchers: Darwins principles say cancer will always evolve to resist treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... August 22, 2017 , ... TopConsumerReviews.com recently gave a best-in-class 5-star rating ... , As the stress of modern life continually makes more demands on time and ... artificial stimulants can trap people in vicious high/low cycles and can also cause long ...
(Date:8/21/2017)... ... August 22, 2017 , ... PracticeMatch, a company that provides online ... with physicians and advanced practitioners like nurse practitioners and physician assistants ... through November of this year. The online career fairs will allow job seekers to ...
(Date:8/21/2017)... ... 21, 2017 , ... Los Angeles area medical group Beverly ... year 2017-2018, Christina M. Busuito, M.D. and Lukasz Swistun, M.D. This one year ... Reconstructive Surgery. The candidate will have the opportunity to work with leading ...
(Date:8/21/2017)... California (PRWEB) , ... August 21, 2017 , ... Five ... money and awareness for Alzheimer’s Family Center. , Guests will be able to ... Newport Beach Plaza, Braised Lamb Shank with Fennel Dill Salad, Feta Cheese Sauce & ...
(Date:8/21/2017)... ... ... The experts have spoken. Prolonged sitting and standing are a no-no for ... healthy way these days? FlexiSpot, one of the fastest-growing manufacturers of ergonomic office solutions, ... Deskcise Pro™– the world’s first sit-stand-cycle desk to backers worldwide. , The Launch , ...
Breaking Medicine News(10 mins):
(Date:7/31/2017)...  Diplomat Pharmacy, Inc. (NYSE: DPLO), has been named one ... by Crain,s Detroit Business . The annual ... three-year revenue growth. This year,s edition measures growth from 2013 ... the complete list, visit crainsdetroit.com/awards/fast_50/2017 .  ... said Phil Hagerman , CEO and chairman of Diplomat. ...
(Date:7/28/2017)... CHICAGO, July 28, 2017 Hill-Rom Holdings, Inc. ... fiscal third quarter ended June 30, 2017, and updated ... For the fiscal third quarter, ... to $0.68 per diluted share in the prior-year period. ... of $0.39 per diluted share primarily related to the ...
(Date:7/27/2017)... 2017  West Pharmaceutical Services, Inc. (NYSE: ... second-quarter 2017 and updated financial guidance for the full-year ... Highlights Reported net sales of $397.6 ... quarter. Net sales at constant currency (organic) grew by ... $0.51, compared to $0.60 in the prior-year quarter. Second-quarter ...
Breaking Medicine Technology: